GNA Biosolutions Reveals New Ultrafast PCR Platform at Medical Trade Show
|
By LabMedica International staff writers Posted on 15 Nov 2017 |

Image: The Pharos V8 laser PCR platform (Photo courtesy of GNA Biosolutions).
GNA Biosolutions GmbH (Martinsried, Germany), a molecular technology company, will showcase its new Pharos V8, the world's first laser PCR platform, at MEDICA 2017.
GNA Biosolutions specializes in sample-to-result applications across medical diagnostics, biosecurity, food safety, and life sciences. The company develops instruments, OEM modules and applications for ultrafast molecular assays based on proprietary technology protected by a comprehensive patent portfolio.
The Pharos V8, an ultrafast PCR instrument for in vitro research use, uses the patented Laser PCR technology, which operates on the same principles as conventional nucleic acid amplification with PCR (Polymerase Chain Reaction). However, Laser PCR uses nanomaterials to control temperature cycles at the nano scale, accelerating PCR reaction times by a factor of ten and opening the door for applications in multiple time-sensitive settings.
Some of the key features of the Pharos V8 include an open platform for universal PCR assay development, ultrafast real-time nucleic acid detection in 10 minutes or less, and intuitive interface with easy-to-use software that can be accessed remotely.
“We are excited to present our first Laser PCR platform, the Pharos V8, at this year's Medica,” said Frank Krieg-Schneider, CEO of GNA Biosolutions. “We believe the Pharos V8 will demonstrate the power of our patented technology to deliver ultrafast molecular results, and pave the way for additional platforms in development for diagnostic testing and point of care.”
Related Links:
GNA Biosolutions
GNA Biosolutions specializes in sample-to-result applications across medical diagnostics, biosecurity, food safety, and life sciences. The company develops instruments, OEM modules and applications for ultrafast molecular assays based on proprietary technology protected by a comprehensive patent portfolio.
The Pharos V8, an ultrafast PCR instrument for in vitro research use, uses the patented Laser PCR technology, which operates on the same principles as conventional nucleic acid amplification with PCR (Polymerase Chain Reaction). However, Laser PCR uses nanomaterials to control temperature cycles at the nano scale, accelerating PCR reaction times by a factor of ten and opening the door for applications in multiple time-sensitive settings.
Some of the key features of the Pharos V8 include an open platform for universal PCR assay development, ultrafast real-time nucleic acid detection in 10 minutes or less, and intuitive interface with easy-to-use software that can be accessed remotely.
“We are excited to present our first Laser PCR platform, the Pharos V8, at this year's Medica,” said Frank Krieg-Schneider, CEO of GNA Biosolutions. “We believe the Pharos V8 will demonstrate the power of our patented technology to deliver ultrafast molecular results, and pave the way for additional platforms in development for diagnostic testing and point of care.”
Related Links:
GNA Biosolutions
Latest Industry News
- Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
- Integrated DNA Technologies Expands into Clinical Diagnostics
- Co-Diagnostics Agreement Expands Commercial and Distribution Reach in South Asia
- Automated MSI Test Gains IVDR Certification to Guide CRC Therapy
- New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network
- MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
- Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
- Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
- QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
- WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
Bile duct strictures can arise from cancer or benign disease, but their location within ducts connecting the liver, gallbladder, and intestines complicates evaluation. Standard biopsy and cytology may... Read moreAdaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
PCR amplification during next-generation sequencing (NGS) library preparation can introduce variability, often requiring manual quantification and risking over-cycling artifacts. The issue is especially... Read more
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Rapid Urine Test Speeds Antibiotic Selection for UTIs
Urinary tract infections are a common reason for antibiotic prescribing and have led to more than 800,000 hospital admissions across England in the past five years, according to National Health Service data.... Read more
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read morePathology
view channel
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
Lunit (Seoul, South Korea), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta (Montreal, QC, Canada), a global contract research organization (CRO) laboratory serving... Read more








